作者: Neda Haghighat , Majid Mohammadshahi , Shokouh Shayanpour , Mohammad Hossein Haghighizadeh
DOI: 10.1007/S12602-018-9509-5
关键词: Lactobacillus acidophilus 、 Bifidobacterium bifidum 、 Synbiotics 、 Probiotic 、 Gastroenterology 、 Placebo 、 Randomized controlled trial 、 Internal medicine 、 Hemodialysis 、 Bifidobacterium longum 、 Medicine
摘要: The aim of this study was to investigate the effects probiotic and synbiotic supplementation on serum inflammatory markers, endotoxin, anti-HSP70 in hemodialysis (HD) patients. This a randomized, double-blind, placebo-controlled trial. Seventy-five patients who met inclusion exclusion criteria were randomly assigned for 12 weeks one three arms: synbiotics [n = 23; 15 g prebiotics, 5 powder containing Lactobacillus acidophilus T16, Bifidobacterium bifidum BIA-6, lactis longum LAF-5 (2.7 × 107 CFU/g each)], probiotics as group with maltodextrin sachet placebo], placebo 19; 20 sachet]. Blood feces collected at baseline after intervention. Serum high sensitive C-reactive protein (hs-CRP), interleukin-6, anti-heat shock 70 antibodies (anti-HSP70) measured. number fecal colonies determined using plate-counting method. mean level hs-CRP, anti-HSP70, endotoxin decreased significantly between groups (p 0.007, p 0.037, 0.036, respectively). For group, changes hs-CRP IL-6 lower than < 0.001 0.001, respectively) 0.011 0.008, Anti-HSP70 differed from 0.002 0.013, Administration more effective improvement levels. Trial registration number: IRCT2017041233393N1.